Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* High-risk proliferative diabetic retinopathy (HR-PDR) eyes.~* Best Corrected-Visual Acuity at baseline \> 20/320 in the study eye.~* Clear ocular media and adequate pupillary dilatation to permit good quality fundus photography.~* Intraocular pressure \< 21 mmHg.~* Type I, or Type II diabetic subjects as defined by the World Health Organization criteria of either gender, and aged ≥ 18 years.~* Women must be using effective contraception, be post-menopausal for at least 12 months prior to trial entry, or surgically sterile.~* Ability to provide written informed consent.~* Ability to return for all trial visits.~Exclusion Criteria:~* Eyes with prior scatter (panretinal) or focal/grid photocoagulation, within the previous 6 months.~* Fibrovascular proliferation with retinal traction.~* Other cause of retinal neovascularization (retinal vein occlusion, radiation retinopathy or others).~* Atrophy/scarring/fibrosis/ hard exudates involving the center of the macula.~* Subjects who have received yttrium-aluminum-garnet laser, or peripheral retinal cryoablation, or laser retinopexy (for retinal tears only), or focal/grid photocoagulation, within the previous 6 months.~* Significant media opacities, which might interfere with visual acuity, assessment of toxicity or fundus photography.~* Subjects should not be entered if there is likelihood that they will require cataract surgery within the following 1 year.~* Any intraocular surgery within 6 months before trial enrollment.~* Previous vitrectomy.~* HbA1C level \>11% or recent signs of uncontrolled diabetes.~* Any of the following underlying systemic diseases:~  * History or evidence of severe cardiac disease.~ * History or evidence of clinically significant peripheral vascular disease such as intermittent claudication or prior amputation.~ * Clinically significant impaired renal function (serum creatinine \>2.5 mg/dL or s/p renal transplant or receiving dialysis).~ * Clinically significant impaired hepatic function.~ * Stroke (within 12 months of trial entry).~ * Any major surgical procedure within one month before trial enrollment.~* Previous radiation to the head in the region of the study eye.~* Any prior treatment with an investigational agent for diabetic retinopathy or anti-VEGF therapy (including intravitreal, subconjunctival or subtenons corticosteroids) during the past 90 days for any other condition.~* Known serious allergies to fluorescein used in angiography, or to components of Lucentis® formulation.~* Systolic Blood Pressure \> 170 (2 different readings) or diastolic Blood Pressure \> 100 (2 different readings).~* Acute ocular or periocular infection.~* Previous filtering surgery (e.g., trabeculectomy) or placement of a glaucoma drainage device (e.g., tube-shunt surgery).~* Use of other investigational drugs at the time of enrollment.~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL).~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means using a highly effective method of birth control. Periodic abstinence are not acceptable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panretinal Photocoagulation (PRP) (Type: ACTIVE_COMPARATOR): Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
- Ranibizumab (Type: EXPERIMENTAL): Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
- Ranibizumab + Panretinal Photocoagulation (PRP) (Type: EXPERIMENTAL): Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.

Based on this trial design, predict the completion outcome and termination type (if applicable).